

Abbott unveils HBsAg Next Assay in India to detect Hepatitis B

09 May 2022 | News

Assay to help detect HBV infections and mutants at an earlier stage even in vaccinated individuals



Abbott has launched HBsAg Next Qualitative solution in India to enhance the detection of the Hepatitis B virus (HBV). This assay will help improve patient outcomes while maintaining safe blood supplies.

The sensitive chemiluminescent microparticle immunoassay (CMIA) assists in the early and enhanced detection of HBV in human serum and plasma (blood) samples and population screening.

The HBsAg Next Qualitative assay is an advanced, next-generation solution to better support the earlier detection of HBV. It detects HBV surface antigen (HBsAg) in human serum and plasma. Moreover, it overcomes traditional challenges by showcasing the highest level of assay performance required to detect infection in immunocompromised groups.